AIToday
AI Business & IndustryFortune AIPublished: Apr 18, 2026, 19:00 JST

Biotech IPO market rebounds as investor interest in GLP-1 drugs and diagnostic innovation challenges AI's dominance in venture funding

Biotech IPO market rebounds as investor interest in GLP-1 drugs and diagnostic innovation challenges AI's dominance in venture funding

Kailera and Alamar are leading a resurgence in biotech IPOs after a period of investor drought in the life sciences sector

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleNebius and TD SYNNEX partner to commercialize NVIDIA HGX B300 GPU clusters for enterprise AI workloads through global distribution channels.